Patents Assigned to The General Hospital Corporation, a Massachusetts corporation
-
Publication number: 20040247579Abstract: A method of inducing tolerance without whole body irradiation.Type: ApplicationFiled: October 29, 2003Publication date: December 9, 2004Applicant: The General Hospital Corporation, a Massachusetts corporationInventor: Megan Sykes
-
Publication number: 20040248178Abstract: &bgr;-netrin nucleic acid molecules and polypeptides are provided. Methods of using the &bgr;-netrin nucleic acid molecules and polypeptides are also provided.Type: ApplicationFiled: April 26, 2004Publication date: December 9, 2004Applicant: The General Hospital Corporation, a Massachusetts corporationInventors: Pamela Olson, Dale Hunter, William Brunken, Manuel Koch, Robert Burgeson
-
Publication number: 20040241096Abstract: The invention features methods of detecting enzymatic activity (e.g., in a magnetic resonance image). In general, the methods include: (1) providing a monomeric substrate (e.g., a substrate that is polymerizable in the presence of an enzyme or as a result of an enzyme-catalyzed reaction), having the generic structure X-Y-Z, where X includes a chelator moiety having a chelated paramagnetic or superparamagnetic metal atom or ion, Y includes a linker moiety (e.g., to provide a covalent or non-covalent chemical bond or bonds between X and Z), and Z includes a polymerizing moiety; (2) contacting the substrate with a target tissue, wherein the substrate undergoes polymerization to form a paramagnetic or superparamagnetic polymer, the polymerization being catalyzed by an enzyme in an extracellular matrix or bound to the surfaces of cells of the target tissue; and (3) detecting an increase in relaxivity for the polymer relative to an equivalent amount of unpolymerized substrate.Type: ApplicationFiled: April 30, 2004Publication date: December 2, 2004Applicant: The General Hospital Corporation, a Massachusetts corporationInventors: Alexei Bogdanov, Ralph Weissleder
-
Publication number: 20040208881Abstract: Antibodies directed against laiminin B1k are provided.Type: ApplicationFiled: May 7, 2004Publication date: October 21, 2004Applicants: The General Hospital Corporation, a Massachusetts corporation, The State Board of Higher Education on behalf of Oregon Health Sciences UniversityInventors: Robert E. Burgeson, David Wolfe Wagman
-
Publication number: 20040185435Abstract: Purified nucleic acid which can specifically hybridize with the sequence of swine retroviruses.Type: ApplicationFiled: November 26, 2003Publication date: September 23, 2004Applicant: The General Hospital Corporation, a Massachusetts corporationInventor: Jay A. Fishman
-
Publication number: 20040170611Abstract: The invention features methods of promoting hair growth in a subject. The methods include inducing or mimicking the effects of Wnt promoted signal transduction, e.g., by increasing the level of Wnt protein or administering an agent which mimics an effect of Wnt promoted signal transduction, e.g., by administering lithium chloride. Methods of inhibiting hair growth are also provided.Type: ApplicationFiled: March 2, 2004Publication date: September 2, 2004Applicant: The General Hospital Corporation, a Massachusetts corporationInventors: Bruce A. Morgan, Jiro Kishimoto, Robert Burgeson
-
Publication number: 20040158192Abstract: A method for delivering compounds through epithelial cell layers using impulse transients is described. The method involves applying a compound to, e.g., the stratum corneum, of a patient and then inducing impulse transients to create transient increases in the permeability of epithelial tissue, thereby facilitating delivery of the compound across the epithelial cell layer.Type: ApplicationFiled: February 5, 2004Publication date: August 12, 2004Applicant: The General Hospital Corporation, a Massachusetts corporationInventors: Nikiforos Kollias, Apostolos G. Doukas, Thomas J. Flotte, Daniel J. McAuliffe, Shun Lee
-
Publication number: 20040096523Abstract: A method for lessening or preventing non-pulmonary ischemia-reperfusion injury or inflammation in a mammal by identifying a mammal which has ischemia-reperfusion or is at risk for developing ischemia-reperfusion in a non-pulmonary tissue; and causing the mammal to inhale a therapeutically effective amount of gaseous nitric oxide sufficient to diminish the ability of leukocytes or platelets to become activated in a manner that contributes to an inflammatory process at the site of the ischemia-reperfusion or inflammation in the non-pulmonary tissue, thereby lessening or preventing non-pulmonary ischemia-reperfusion injury in the mammal.Type: ApplicationFiled: October 27, 2003Publication date: May 20, 2004Applicant: The General Hospital Corporation, a Massachusetts corporationInventors: Warren M. Zapol, Kenneth D. Bloch, Anthony Rosenzweig
-
Publication number: 20040092530Abstract: The invention provides methods for treating neuropsychiatric disorders such as schizophrenia, Alzheimer's Disease, autism, depression, benign forgetfulness, childhood learning disorders, closed head injury, and attention deficit disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) a therapeutically effective amount of D-alanine (or a modified form thereof), provided that the composition is substantially free of D-cycloserine, and/or (ii) D-serine (or a modified form thereof), and/or (iii) 105 to 500 mg of D-cycloserine (or a modified form thereof), and/or (iv) N-methylglycine (or a modified form thereof).Type: ApplicationFiled: September 23, 2003Publication date: May 13, 2004Applicant: The General Hospital Corporation, a Massachusetts corporationInventors: Guochuan Tsai, Joseph Coyle
-
Publication number: 20040047804Abstract: The invention features new methods of enhanced radiation therapy based on the discovery that by using controlled combinations of (i) specific radiodense compositions, (ii) specific modes of administration of these radiodense compositions, and (iii) specific energy bands and sources of radiation, that the effect of radiation on tumors and other diseased tissues can be effectively and safely enhanced to provide significantly improved radiation therapy.Type: ApplicationFiled: August 12, 2003Publication date: March 11, 2004Applicant: The General Hospital Corporation, a Massachusetts corporationInventors: Gerald L. Wolf, Gregory L. McIntire, Edward R. Bacon
-
Publication number: 20040029209Abstract: The invention relates to devices and methods for growing cells in vitro in an enclosed device that allows for a three-dimensional measurement over time of both their proliferative and/or invasive properties. By growing the cells in an enclosed matrix that resembles the environment that the cells confront in vivo, the cells can divide, invade, and form branched networks as they do in living tissue, e.g., in an individual. The devices of the invention include a test chamber in which cells, e.g., tumor cells, are placed and permitted to divide and/or invade. Cells can be placed within an insert within a chamber of the device. A delivery chamber that connects to the test chamber enables the delivery of agents that can be studied, e.g., for their therapeutic potential. The assay devices of the invention can be used as model systems to study cancer biology and to evaluate the efficacy of anti-cancer therapeutics.Type: ApplicationFiled: February 12, 2003Publication date: February 12, 2004Applicant: The General Hospital Corporation, a Massachusetts corporationInventors: Thomas S. Deisboeck, E. Antonio Chiocca, John D. Wright
-
Publication number: 20040029872Abstract: The invention provides methods for inhibiting psychostimulant-induced or nicotine-induced craving of additional psychostimulants (e.g., cocaine or amphetamine) or nicotine. In these methods, D1-like antagonists or D1-like agonists are administered to a patient dependent on psychostimulant drugs or nicotine and therefore susceptible to, or suffering from, such a craving. Also disclosed is an animal model system useful for measuring the ability of test compounds to inhibit psychostimulant-induced or nicotine-induced cravings in humans.Type: ApplicationFiled: February 10, 2003Publication date: February 12, 2004Applicant: The General Hospital Corporation, a Massachusetts corporationInventors: Hans C. Breiter, Bruce R. Rosen, John J. A. Marota, Joseph B. Mandeville, Barry E. Kosofsky
-
Publication number: 20040023856Abstract: Recombinant laminin B1k and fragments thereof.Type: ApplicationFiled: May 22, 2003Publication date: February 5, 2004Applicants: The General Hospital Corporation, a Massachusetts corporation, State Board of Higher Education on behalf of Oregon Health Sciences UniversityInventors: Robert E. Burgeson, David Wolfe Wagman
-
Publication number: 20030219383Abstract: An intramolecularly-quenched, near infrared fluorescence probe that emits substantial fluorescence only after interaction with a target tissue (i.e., activation) is disclosed. The probe includes a polymeric backbone and a plurality of near infrared fluorochromes covalently linked to the backbone at fluorescence-quenching interaction-permissive positions separable by enzymatic cleavage at fluorescence activation sites. The probe optionally includes protective chains or fluorochrome spacers, or both. Also disclosed are methods of using the intramolecularly-quenched, near infrared fluorescence probes for in vivo optical imaging.Type: ApplicationFiled: February 7, 2003Publication date: November 27, 2003Applicant: The General Hospital Corporation, a Massachusetts corporationInventors: Ralph Weissleder, Ching-Hsuan Tung, Umar Mahmood, Lee Josephson, Alexei Bogdanov
-
Publication number: 20030207844Abstract: Methods, compositions, and kits, are provided for the use of nitric oxide synthase inhibitors to prevent and reduce wrinkles.Type: ApplicationFiled: April 3, 2003Publication date: November 6, 2003Applicant: The General Hospital Corporation, a Massachusetts corporationInventors: Ethan Lerner, Seishiro Fujii
-
Publication number: 20030157685Abstract: The present invention relates to three novel cancer related genes, Nmi, Omi and Rim. The Nmi gene encodes a myc gene product-binding protein. The Omi gene encodes a mammalian serine protease protein comprising an amino terminal regulatory domain, which includes a signal peptidase site, a triple repeat motif, an SH3 binding domain, and a consensus Mxi2/p38 kinase phosphorylation site, and a carboxy terminus serine protease catalytic domain. The retinoblastoma-interacting myosin-like gene (Rim gene) encodes a retinoblastoma binding protein comprising two leucine zipper structures, an RB family binding motif, an E1A/CtBP binding motif, and four nuclear localization sequences. Described herein are isolated and antisense nucleic acids molecules, recombinant expression vectors, host cells and non-human transgenic animals containing an insertion or a disruption of the Nmi, Omi and Rim genes. Diagnostic, screening and therapeutic methods utilizing the compositions of the invention are also provided.Type: ApplicationFiled: August 9, 2002Publication date: August 21, 2003Applicant: The General Hospital Corporation, a Massachusetts corporationInventor: Antonis S. Zervos
-
Publication number: 20030153041Abstract: DNA encoding a parathyroid hormone receptor; production and isolation of recombinant and synthetic parathyroid hormone receptor polypeptides and fragments; antibodies to parathyroid hormone receptors and receptor fragments; methods for screening candidate compounds for antagonistic or agonistic effects on parathyroid hormone receptor action; and diagnostic and therapeutic methods of these compounds are disclosed.Type: ApplicationFiled: October 9, 2002Publication date: August 14, 2003Applicant: The General Hospital Corporation, a Massachusetts corporationInventors: Gino V. Segre, Henry M. Kronenberg, Abdul-Badi Abou-Samra, Harald Juppner, John T. Potts, Ernestina Schipani
-
Publication number: 20030113540Abstract: The present invention provides microparticles that create permanent tissue markings, such as tattoos, designed in advance for change and/or removal on demand, as well as methods for implanting the microparticles in tissue and changing and/or removing the resulting markings. Colored microparticles are constructed with specific electromagnetic absorption and/or structural properties that facilitate changing and/or removing tissue markings made using the microparticles by applying specific energy (such as electromagnetic radiation from a laser or flash-lamp) to the tissue marking site.Type: ApplicationFiled: January 10, 2003Publication date: June 19, 2003Applicant: The General Hospital Corporation, a Massachusetts corporationInventors: Richard R. Anderson, Susanna K. Mlynarczyk, Craig A. Drill
-
Publication number: 20030095941Abstract: An anti-reflective cosmetic composition for skin is disclosed. The composition includes a material that, when applied to skin, forms a layer of the material that adheres to the skin, has a thickness of from about 60 nm to about 140 nm, and a refractive index of between about 1.1 and 1.4. The layer reduces the Fresnel component of light reflected from skin. In addition, cosmetic compositions that include colored, shaped additives that mimic the appearance of colored structures in healthy skin are disclosed.Type: ApplicationFiled: December 6, 2002Publication date: May 22, 2003Applicant: The General Hospital Corporation, a Massachusetts corporationInventor: Richard R. Anderson
-
Publication number: 20030072752Abstract: A method of modulating cell proliferation or apoptosis comprising modulating psoriastatin activity.Type: ApplicationFiled: October 16, 1996Publication date: April 17, 2003Applicant: General Hospital Corporation, a Massachusetts corporationInventors: TOSHIHIKO HIBINO, TADAHITO TAKAHASHI, PETER C. BACIU, PAUL F. GOETINCK